Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)open accessCurrent Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
- Authors
- 조형우; 윤덕현; 신동엽; 고영일; 윤성수; 김석진; 도영록; 이경원; 곽재용; 박용; 김민경; 강혜진; 이준호; 유쾌한; 이원식; 박병배; 조재철; 엄현석; 김효정; 정성현; 원영웅; 손병석; 권지현; 서철원; 김원석
- Issue Date
- Apr-2023
- Publisher
- 대한암학회
- Keywords
- Peripheral T-cell lymphoma; Treatment pattern; Autologous stem cell transplantation
- Citation
- Cancer Research and Treatment, v.55, no.2, pp 684 - 692
- Pages
- 9
- Journal Title
- Cancer Research and Treatment
- Volume
- 55
- Number
- 2
- Start Page
- 684
- End Page
- 692
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/68487
- DOI
- 10.4143/crt.2022.1434
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.